Clinical Trial Update: Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial assessing the efficacy and safety of tideglusib in congenital myotonic dystrophy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Myotonic Dystrophy

Drugs mentioned

• Tideglusib (tideglusib)

Snippet

Sponsor: AMO Pharma Limited | Conditions: Congenital Myotonic Dystrophy | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-09-11